A study found that prostate-specific antigen (PSA) doubling time (DT) is a robust clinical predictor for disease progression and survival in newly diagnosed metastatic castration-naïve prostate cancer (mCNPC). The findings were published in the Journal of Oncology.
In this study, researchers retrieved data on 648 patients with newly diagnosed mCNPC receiving androgen deprivation therapy at Chang Gung Memorial Hospital from January 2007 to December 2016. Basic characteristics and PSA kinetics profile were subsequently evaluated, they noted.
According to the results, over 48% of patients with low-volume disease progressed to metatastic castration-resistant prostate cancer (mCRPC). In the overall population, those who progressed to CRPC had significantly shorter time to PSA nadir (TTN) and faster time from PSA nadir to CRPC (TFNTC) (P< 0.001) compared to the non-CRPC group. The researchers noted that PSADT of less than four months tended to be associated with faster disease progression and shorter overall survival (OS).
“PSADT is an effective clinical predictor for disease progression and survival in low-volume disease,” the researchers concluded. “Other PSA kinetics including TTN and TFNTC, though not the major predictors for disease progression or OS in LVD, might be the predictors for disease control status.”